Formulation Development and Evaluation of Immediate Release Tablet Dosage form of Sorafenib Tosylate Dr Reddy Y. Krishna*, Kalpana D. Department of Pharmaceutics, Nalanda College of Pharmacy, Jawaharlal Nehru Technological University, Hyderabad, Telangana *Corresponding Author E-mail: rajinisuralabs1@gmail.com
Online published on 3 June, 2020. Abstract Immediate release drug formulation is a novel type of drug delivery system which disintegrates rapidly and gets dissolved to release the medicaments after administration. Sorafenib tosylate is kinase inhibitors, used to treat renal cell carcinoma. our work involves the formulation, optimization and post compressed evaluation studies of immediate release Sorafenib tosylate tablets. The direct compression method was employed for formulating tablets. Tablet composition contains Sorafenib tosylate as a filler. Explotab, Solutab and polyplasdone XL is a superdisintegrant, mannitol as sweeting agent magnesium stearate as a lubricant, talc as a anticaking agent. The prepared tablets were evaluated for physico-chemical properties and post evaluation studies such as drug content and in vitro dissolution. Further more, Finally, it was concluded that all the pre-formulation and post compression studies of sorafenib tablet met with required specifications and also showed comparably a good rate of dissolution like that of a commercial product. Among all the formulations F6 formulation containing, drug and Solutab showed good result that is 99.56% in 45 min. Hence from the dissolution data it was evident that F6 formulation is the better formulation. Top Keywords Sorafenib tosylate, Explotab, Solutab, Polyplasdone XL and Immediate release. Top |